P309: Supply Chain Under Stress: A Data-Driven Analysis of Vulnerable Medicines
Poster Presenter
Allison Radwick
Senior Regulatory and Policy Communications Manager
US Pharmacopeia United States
Objectives
Drug shortages threaten patient care. Analysis of the 2024-2025 Vulnerable Medicines List identified 100 essential medications through assessment of manufacturing complexity, geographic concentration, and therapeutic criticality, revealing patterns to strengthen supply chain resilience.
Method
This study used a Factor Analysis of Mixed Data method to evaluate medicine criticality and USP Medicine Supply Map risk scores to assess vulnerability. Analysis covered 2,300 drugs across acute and chronic categories, examining manufacturing patterns, geographic concentration, and quality metrics.
Results
Our analysis reveals significant vulnerabilities in medical supply chains, with injectable formulations representing 71% of at-risk medicines. Geographic concentration of manufacturing emerges as a critical risk factor, while complex manufacturing processes strongly correlate with higher rates of supply disruption. Notably, we identified 12 essential medicines with no viable therapeutic alternatives, highlighting critical gaps in supply chain resilience.
The distribution of vulnerable medicines spans key therapeutic classes across both chronic and acute care settings. For chronic conditions, the most affected categories include cardiovascular agents, central nervous system medications, respiratory treatments, antidiabetic medicines, and mental health therapeutics. In acute care, significant vulnerabilities exist in pain management drugs, oncology treatments, hospital solutions, and antibacterial medications.
Several critical risk factors contribute to supply chain instability. Manufacturing complexity directly impacts production stability, while price pressures threaten long-term production sustainability. Persistent quality control challenges affect multiple therapeutic categories, and the concentration of production locations increases vulnerability. Limited redundancy in supply chains further compounds these risks, creating potential single points of failure in the medical supply system.
Conclusion
This analysis reveals critical vulnerabilities in both chronic and acute medicine supply chains, with injectable formulations facing particularly high risks. The findings suggest that strengthening supply chain resilience requires a multi-faceted approach focusing on:
1. Diversifying manufacturing locations
2. Supporting complex manufacturing capabilities
3. Developing alternative supply sources for critical medicines
4. Implementing early warning systems for potential disruptions
5. Creating incentives for maintaining production of essential medicines
These interventions must be tailored to address the distinct challenges facing chronic and acute medicines while maintaining robust quality standards across both categories.
